09:50 AM EST - Intellipharmaceutics International Inc. : announced that it has notified the U.S. Food and Drug Administration (FDA) that it has not received notification of any patent infringement proceedings by the brand owner, Wyeth Pharmaceuticals, Inc., a wholly-owned subsidiary of Pfizer, Inc., for its application to market a generic of Wyeth's Protonix(R) (delayed-release pantoprazole sodium) tablets. As a result, Intellipharmaceutics will not be subject to the automatic 30-month stay of FDA approval to market the product, and that it will be in a position to market its product in the United States upon FDA approval. Intellipharmaceutics International Inc.
shares T.I are trading up $0.04 at $2.74.
